Open AccessBaseline serum lactate dehydrogenase level predicts survival benefit in patients with metastatic colorectal cancer receiving bevacizumab as first-line chemotherapy: a systematic review and meta-analysis of 7 studies and 1,219 patients
Author(s) -
Feng Wu,
Yue Wang,
Xiaoyan Zhu
Publication year - 2019
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm.2019.02.45
Subject(s) - bevacizumab , medicine , meta analysis , lactate dehydrogenase , colorectal cancer , oncology , hazard ratio , chemotherapy , progression free survival , cancer , confidence interval , biochemistry , chemistry , enzyme